Last updated: May 8, 2026
Albiglutide is a GLP-1 receptor agonist originally developed for type 2 diabetes by GlaxoSmithKline (GSK) and later distributed in the US. The product was discontinued in multiple markets and is no longer a current commercial comparator in most formularies. The clinical development record ends without a confirmed late-stage expansion into additional indications. Post-approval activity is dominated by safety/clinical pharmacology follow-ups and the withdrawal/discontinuation process rather than new phase 3 programs.
What is albiglutide’s current clinical and regulatory status?
Has albiglutide entered new phase 3 or registration trials after approval?
No. The public late-stage portfolio for additional indications does not show ongoing or newly initiated phase 3 programs that culminate in regulatory submissions.
What trials have defined the clinical profile?
The development base is anchored by two pivotal type 2 diabetes outcomes programs and associated cardiovascular safety workstreams:
- HARMONY phase 3 diabetes program (glycemic efficacy and dose comparisons reported through the portfolio of HARMONY trials; the overall phase 3 program supported the original indication).
- HARMONY Outcomes (cardiovascular outcomes trial in type 2 diabetes; reported as albiglutide’s major outcomes evidence package).
What happened to commercialization and why does that shape market visibility?
- US: Tanzeum was withdrawn from the US market.
- Europe and other geographies: Multiple markets followed with discontinuations or limited availability tied to the product lifecycle, competitive class pressure, and manufacturer decisions.
These discontinuations drive a practical outcome for investors and R&D planners: there is limited real-world prescription flow to model, and ongoing clinical trial activity is not paired with sustained commercial scale.
What does the clinical-trial evidence show for efficacy and safety (high level)?
How does albiglutide perform on HbA1c?
Across the HARMONY phase 3 program, albiglutide achieved statistically significant HbA1c reductions vs comparators in the original trial framing used for label support. The magnitude varied by dose and background therapy.
What is the established safety pattern?
The GLP-1 class safety profile applies: gastrointestinal adverse events are the dominant tolerability issue, with injection-site reactions also observed. Cardiovascular safety was addressed in the outcomes program.
How does class competition affect forward-looking value?
GLP-1 market share migrated toward once-weekly and later once-weekly or more potent agents (including molecules with expanded CV indication outcomes, broader label expansion, and stronger payer coverage). When a product is withdrawn, post-withdrawal value shifts to:
- residual value from remaining inventory or legacy reimbursement,
- royalty/licensing (if any),
- limited trial/label maintenance activity rather than new growth.
Which trials are most important for due diligence and investment modeling?
Cardiovascular outcomes and label-defining evidence
- HARMONY Outcomes is the key outcomes trial underpinning CV safety evidence for type 2 diabetes. The trial is repeatedly referenced as the principal cardiovascular outcomes dataset for albiglutide’s class and mechanism.
Dose and phase 3 efficacy dataset
- HARMONY (phase 3 glycemic efficacy program). The trial set established clinical comparators, dose selection rationale, and the maintenance of effects across dosing intervals consistent with the albiglutide schedule.
What is known about post-trial activity and evidence generation?
Post-approval updates focus on:
- cardiovascular safety interpretation,
- pharmacovigilance,
- label lifecycle actions,
- discontinuation logistics.
No sustained evidence stream points to new phase 3 registration paths.
How big is the albiglutide market opportunity today?
Is albiglutide a current growth product?
No. The commercial availability is no longer positioned as an active growth engine.
Market reality after withdrawal
Albiglutide’s opportunity is constrained by:
- product discontinuation in key markets,
- limited physician/payer momentum versus in-class incumbents and newer agents,
- reduced clinical and commercial trial participation compared with active competitors.
What can still be modeled credibly?
Two modelable segments remain:
- Legacy demand and residual inventory (short window; largely expired).
- Academic/registry usage and historical comparators (non-revenue market activity).
Given the withdrawal state, revenue projections based on active launches are not appropriate. A credible projection frame is lifecycle closure rather than growth.
What are the competitive dynamics that displaced albiglutide?
GLP-1 class label expansion and payer adoption
GLP-1 therapies that secured strong cardiovascular outcomes narratives and broad indication expansion captured the payer shift toward preferred status. The competitive set also benefited from:
- stronger evidence perception in CV and weight endpoints,
- increasing dosing convenience and patient adherence.
Drug development tempo
While albiglutide’s later-stage pipeline does not show new phase 3 expansions, competitors continued with:
- new CV outcome trials,
- earlier and broader line-of-therapy uptake,
- label expansions for cardiometabolic and weight management indications.
This dynamic is central to why albiglutide’s market activity stopped moving and why the label history did not translate into sustained commercial momentum.
Market projection: what does a base-case forecast look like?
Because albiglutide is discontinued, forecasting should be treated as a decline-to-zero profile with limited tail risk rather than a product launch growth profile. Under that lifecycle framing:
Base-case projection (lifecycle closure)
- Near-term: minimal or no new prescriptions due to market withdrawal.
- Medium-term: continued absence of new demand; any remaining activity is likely tied to legacy access or exceptional inventory situations.
Scenario set
- Base case: Continued minimal availability; revenue near zero after residual inventory windows end.
- Downside: Complete cessation with faster uptake of alternatives, reducing any residual channel value to zero.
- Upside: Only if a reintroduction occurs through a licensing partner or special access program; no public evidence of that reintroduction exists in the clinical/regulatory trajectory.
This projection is driven by the product lifecycle state rather than by a change in clinical data.
Investment and R&D implications
Does the existing albiglutide dossier enable a platform for new assets?
Yes, at the level of:
- GLP-1 receptor agonist pharmacology learnings,
- dosing and formulation experience for a once-weekly peptide schedule,
- cardiovascular safety interpretation methods and trial design learnings.
It does not, however, create a commercial tail comparable to active GLP-1 leaders because the product itself is no longer positioned for uptake.
Where can stakeholders still create value?
- Clinical and regulatory strategy: outcomes trial frameworks and endpoint selection learnings.
- IP positioning: using albiglutide-era claims or related know-how for new formulations or analogs is possible but not equivalent to an albiglutide re-entry commercial thesis.
Key Takeaways
- Albiglutide’s development story is anchored by the HARMONY phase 3 program and HARMONY Outcomes cardiovascular evidence in type 2 diabetes.
- The product is no longer an active commercial growth product; market visibility is dominated by discontinuation rather than new phase 3 expansion.
- A credible “projection” is lifecycle closure toward near-zero demand rather than a growth forecast.
- Value for stakeholders shifts to dossier-based learnings and IP strategy, not to ongoing market scaling.
FAQs
1) What were albiglutide’s defining clinical trials?
The key programs are the HARMONY phase 3 diabetes program and HARMONY Outcomes for cardiovascular outcomes in type 2 diabetes.
2) Does albiglutide currently have active phase 3 expansion trials in additional indications?
Publicly visible evidence does not show new phase 3 registration programs after the original development cycle.
3) Why is the market projection near zero rather than growth?
Albiglutide is discontinued/withdrawn in major markets, removing the mechanism for sustained prescription growth.
4) What safety profile should be used for historical reference?
The established GLP-1 class pattern applies, with gastrointestinal events as the dominant tolerability issue, supported by cardiovascular safety evaluation in the outcomes program.
5) Can the albiglutide evidence still matter for new GLP-1 programs?
Yes. Its outcomes trial design and clinical pharmacology learnings remain relevant, but commercial value depends on whether a successor product re-enters the market.
References (APA)
[1] New York Times. (2018, March 19). GSK discontinues diabetes drug Tanzeum. https://www.nytimes.com/2018/03/19/health/gsk-discontinues-diabetes-drug-tanzeum.html
[2] FDA. (n.d.). Tanzeum (albiglutide) discontinued information (drug label / FDA resources). https://www.accessdata.fda.gov/ (search “Tanzeum albiglutide discontinued”)
[3] American Diabetes Association. (2018). Standards of medical care in diabetes. Diabetes Care. https://diabetesjournals.org/ (reference for GLP-1 class and CV outcomes context)
[4] HARMONY Outcomes Investigators. (2018). Cardiovascular outcomes with albiglutide in type 2 diabetes (HARMONY Outcomes). (Journal publication record). https://www.nejm.org/ (trial publication index)
[5] GSK. (n.d.). Tanzeum (albiglutide) product and clinical trial information. https://www.gsk.com/ (clinical trial and lifecycle materials)
